

Health PEI

ANTIMICROBIAL STEWARDSHIP SUBCOMMITTEE

Adult Chemical Pneumonitis & Aspiration Pneumonia

Key Messages

- Most people with aspiration **DO NOT** develop pneumonia and can be managed with a **watch and wait approach** - If patient is stable, monitor for signs and symptoms for 48 hours; antibiotics are not required.
- Antibiotic treatment for patients who develop fever, leukocytosis, and infiltrates in the first 48 hours after an aspiration event is likely unnecessary and may only select for resistant organisms
- Piperacillin/tazobactam is NOT first line therapy for hospital acquired “aspiration” pneumonia and should be reserved for patients that are critically ill.
- Routine addition of anaerobic coverage is not recommended unless treating an empyema or lung abscess

Background

- **Aspiration/Chemical Pneumonitis** - an inflammatory response to chemical injury caused by inhalation of sterile gastric contents.
- **Aspiration Pneumonia** - an infectious process caused by the inhalation of oropharyngeal secretions that are colonized by pathogenic bacteria. Slow onset/non-acute process with persistent fever and hypoxemia.
- **Risk factors for aspiration pneumonia:** dysphagia; degenerative neurologic diseases (e.g. dementia, post-stroke, Parkinson’s disease, multiple sclerosis); anatomical abnormality or mechanical interference of upper gastrointestinal tract (e.g. enteral feeding, nasogastric tube, endotracheal intubation); esophageal disorders (e.g. strictures, vomiting + small bowel obstruction, achalasia); altered level of consciousness (e.g. acute alcohol or substance abuse, seizures, CNS depressants, etc.); and cardiac arrest

Most Common Organisms

- **Aspiration/Chemical Pneumonitis** – sterile process, no organisms involved.
- **Aspiration Pneumonia** - Usual pathogens (depending on clinical scenario): *S. pneumoniae*, *H. influenzae*, *S. aureus*, Enterobacteriaceae, *Pseudomonas aeruginosa* (nosocomial), oral anaerobes, Streptococcus spp. Role of anaerobes controversial and historically has been overemphasized.

Treatment Criteria and Considerations

| Aspiration/Chemical Pneumonitis |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description |
| <ul style="list-style-type: none">- Episode of macroaspiration is often witnessed and typically occurs in patients with decreased level of consciousness- Characterized by a sudden onset of prominent dyspnea, tachycardia, hypoxemia, low-grade fever, and crackles or diffuse wheeze- Symptoms may range from mild to severe and can develop within 2 to 5 hours- Pulmonary infiltrates are apparent on x-ray |
| Management |
| <ul style="list-style-type: none">⇒ Prophylactic antimicrobial therapy is NOT indicated⇒ Corticosteroids do not have a proven benefit⇒ Recommend supportive care with humidified oxygen and chest physio⇒ Reassess patient in 24-48 hours – may consider antibiotic therapy if signs and symptoms lasting greater than 48 hours (i.e. fever, cough, leukocytosis), x-ray evidence of infiltrate AND risk factors (receiving gastric acid suppression or enteral feeds, has a small bowel obstruction or gastroparesis) <p><u>Rapid clinical improvement within 24 to 48 hours typically indicates lack of pneumonia – if antimicrobial therapy was initiated then consider discontinuing</u></p> |
| Clinical Pearls |
| <ul style="list-style-type: none">- Employ measures to reduce future aspiration episodes (encouraging quality oral care, elevate head of bed, minimize time in supine position and reassess medications associated with CNS depression; consider swallowing assessment) |

Health PEI

ANTIMICROBIAL STEWARDSHIP SUBCOMMITTEE

| Aspiration Pneumonia | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Description | |
| <ul style="list-style-type: none">- Most are indistinguishable from CAP and HAP- Slow onset over several days after aspiration event- Usually a clinical diagnosis in a patient with predisposing risk factors to aspiration, compatible radiographic evidence occurring in dependent lung segment and characteristic clinical history indicative of infection (e.g. fever, cough, tachypnea, dyspnea, purulent sputum etc.)- Right lower lobe most commonly implicated in ambulatory patients.- Posterior upper and superior lower lobes most commonly implicated in bed bound patients | |
| Management | |
| Community Acquired | If meets treatment criteria, refer to empiric treatment table in Health PEI Community Acquired Pneumonia guideline |
| Hospital Acquired | If meets treatment criteria, refer to empiric treatment table in Health PEI Hospital Acquired Pneumonia guideline |
| Clinical Pearls | |
| <ul style="list-style-type: none">- Most clinically important anaerobes are adequately covered by amoxicillin-clavulanate, piperacillin-tazobactam and meropenem- Routine addition of anaerobic coverage is not recommended unless treating an empyema or lung abscess- Atypical coverage is not required in aspiration pneumonia- Sputum samples are unsuitable due to inevitable contamination by normal flora.- Do not treat Candida spp found in sputum unless systemic candidiasis suspected (e.g. neutropenic, transplant patients, etc.)- For immunocompromised patients, recommend consulting infectious disease | |

These guidelines are an adaptation of New Brunswick Anti-infective Stewardship Committee **Adult Chemical Pneumonitis & Aspiration Pneumonia**

References:

1. DiBardino DM, Wunderink RG. Aspiration pneumonia: A review of modern trends. J Crit Care. 2015 Feb;30(1):40-8.
2. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001 Mar 1;344(9):665-71.
3. Japanese Respiratory Society. Aspiration Pneumonia. Respirology. 2009 Nov;14 Suppl 2:S59-64.
4. Komiya K, Ishii H, Kadota J. Healthcare-associated Pneumonia and Aspiration Pneumonia. Aging Dis. 2014 Feb 8;6(1):27-37.
5. Blondel-Hill E, Fryters S. Bugs & Drugs App. Edmonton: Capital Health (Accessed January 25, 2023)
6. Bartlett JG. Aspiration Pneumonia in Adults. In: UpToDate, Sexton DJ (Ed), UpToDate, Waltham, MA. (Accessed on August 8, 2019.)
7. Vlad Dragan, Yanliang Wei, Marion Elligsen, Alex Kiss, Sandra A N Walker, Jerome A Leis, Prophylactic Antimicrobial Therapy for Acute Aspiration Pneumonitis, Clinical Infectious Diseases, Volume 67, Issue 4, 15 August 2018, Pages 513–518, <https://doi.org/10.1093/cid/ciy120>
8. Firstline Mobile Health App. NS Health; Eastern Health St. Johns; Island Health Vancouver; AHS Calgary Zone; Fraser Health BC; Providence Health Care Vancouver; Saskatchewan Health Authority. (Accessed January 25, 2023)
9. Mandell LA, Niederman MS. Aspiration Pneumonia. New England Journal of Medicine. 2019;380(7):651

Health PEI

ANTIMICROBIAL STEWARDSHIP SUBCOMMITTEE